Core Viewpoint - The stock of InnoCare Pharma (09606) rose nearly 3% in early trading, currently up 2.23% at 301 HKD, with a trading volume of 18.1 million HKD, following the announcement that its partner Avenzo Therapeutics received FDA fast track designation for its EGFR/HER3 bispecific antibody drug conjugate AVZO-1418/DB-1418 [1][2]. Group 1 - Avenzo Therapeutics, a clinical-stage biotechnology company focused on next-generation cancer therapies, has been granted fast track designation by the FDA for AVZO-1418/DB-1418, aimed at treating patients with unresectable locally advanced or metastatic non-small cell lung cancer (NSCLC) [1][2]. - The fast track designation is specifically for patients with EGFR mutations (exon 19 deletions or L858R mutations) who have experienced disease progression after treatment with EGFR tyrosine kinase inhibitors (TKIs) [2]. - Currently, AVZO-1418/DB-1418 is undergoing an open-label Phase 1/2 clinical trial to evaluate its safety, tolerability, and preliminary clinical activity as a monotherapy and in combination therapy for patients with advanced solid tumors [2].

Core Viewpoint - The news highlights that EnGene Biotech-B (09606) has seen a stock price increase following the announcement that its partner Avenzo Therapeutics has received Fast Track designation from the FDA for its dual-specific antibody drug conjugate AVZO-1418/DB-1418, aimed at treating non-small cell lung cancer (NSCLC) patients with specific mutations [1][2]. Group 1: Company Developments - EnGene Biotech-B's stock rose nearly 3% in early trading, currently at 301 HKD with a trading volume of 18.1 million HKD [1]. - Avenzo Therapeutics, a clinical-stage biotechnology company, announced the FDA's Fast Track designation for AVZO-1418/DB-1418, which is a significant milestone for the drug's development [1][2]. Group 2: Product and Clinical Trials - The Fast Track designation is specifically for the treatment of patients with unresectable locally advanced or metastatic NSCLC who have specific EGFR mutations and have progressed after TKI treatment [2]. - AVZO-1418/DB-1418 is currently undergoing an open-label Phase 1/2 clinical trial to evaluate its safety, tolerability, and preliminary clinical activity as a monotherapy and in combination therapy for patients with advanced solid tumors [2].

Core Viewpoint - The article emphasizes the importance of the innovation-driven pharmaceutical industry in China, highlighting the trend of internationalization and the potential for growth in both innovative drugs and medical devices, while also addressing the challenges posed by domestic demand and healthcare financing [2][3][4]. Group 1: Innovation and Internationalization - The Chinese innovative pharmaceutical industry has transitioned from "importing and imitating" to "innovating and exporting," with significant internationalization evidenced by increasing license-out deals and collaborations [3][5]. - By 2025, Chinese innovative drugs are expected to demonstrate global competitiveness with high-quality clinical data presented at major international conferences [5][9]. - The trend of innovative drugs is supported by improved financing conditions and a favorable regulatory environment, leading to a new cycle for CXO and upstream sectors [3][4]. Group 2: Domestic Demand and Healthcare Financing - Domestic demand has been weak but is gradually improving, with commercial insurance playing a crucial role in alleviating payment conflicts [3][4]. - The healthcare sector is undergoing a normalization phase post-medical corruption investigations, which is expected to ease the impact on the industry by 2025 [3][4]. - The article highlights the need for a multi-layered healthcare financing system, with commercial insurance expected to inject new vitality into the payment landscape [24][25]. Group 3: Investment Strategies - The "barbell strategy" remains applicable in 2026, combining aggressive investments in innovative healthcare technologies with defensive positions in traditional dividend-paying stocks [4][22]. - The article suggests that high-dividend pharmaceutical stocks still have room for valuation recovery, particularly in light of the aging population and the essential nature of healthcare demand [23][24]. - Key investment windows are identified around the release of 2025 annual reports and the end of 2026, as these periods may attract institutional investment due to clearer assessments of dividend sustainability [23][24]. Group 4: Medical Devices and Equipment - The medical device sector is expected to see a recovery, with companies gradually clearing inventory and improving revenue growth [14][18]. - The article notes that the competitive landscape for medical devices is shifting, with high-end products maintaining price stability while lower-end products face price competition [18][19]. - Chinese medical device companies are accelerating their international expansion, with overseas revenue growth outpacing domestic revenue growth [19][20]. Group 5: Future Outlook - The integration of AI in healthcare is anticipated to create new tools and business models, particularly in drug development and clinical diagnostics [20][21]. - The article posits that while rapid growth in new technologies may be challenging in the short term, supportive policies and clear clinical needs will present investment opportunities in the healthcare sector [21][22].

Core Insights - The QDII funds market has shown strong performance in the first ten months of the year, with 95.1% of the 650 comparable funds reporting net value increases, while only 32 funds experienced declines [1] Fund Performance - The top-performing QDII funds include Huatai-PineBridge Hong Kong Advantage Selected Mixed A and C, both achieving returns of 117.54% and 117.53% respectively [1] - A total of 10 QDII funds recorded gains exceeding 78%, with E Fund's Global Growth Selected Mixed A and C (USD and RMB) each surpassing 83% [2][3] - The leading funds in the innovation drug sector have significantly contributed to the overall performance, with notable funds like the GF CSI Hong Kong Innovation Drug ETF and others achieving returns between 78.11% and 88.09% [3] Investment Focus - The investment strategy of the top-performing funds emphasizes sectors such as innovative pharmaceuticals and high-barrier medical equipment, targeting companies with global competitiveness and growth potential [1][3] - The top holdings of the leading funds include major players in the biotech and pharmaceutical industries, such as TSMC, NVIDIA, and Alibaba [2][3] Market Trends - The innovation drug sector has rebounded, leading to a broad increase in related stocks, which has positively impacted the performance of funds heavily invested in this area [1][3] - Conversely, funds focused on oil and gas, as well as real estate, have underperformed, indicating a sector rotation within the QDII market [4]

Core Insights - Suzhou Wangshan Wangshui Biopharmaceutical Co., Ltd. officially listed on the Hong Kong Stock Exchange, marking the fifth company from Suzhou Industrial Park to go public this year [1][2] - The company was established in 2013 and focuses on innovative small molecule drug development, particularly in the fields of neuropsychiatry, reproductive health, and viral infections [1] - Wangshan Wangshui has a comprehensive integrated system covering the entire drug development process, with two products in commercialization, four in clinical research, and three in preclinical research [1] Company Overview - Wangshan Wangshui's core products include LV232, a treatment for severe depression, and TPN171, a PDE5 inhibitor for erectile dysfunction [1][2] - LV232 is set to enter Phase II clinical trials in China in April 2025, with completion expected in the second half of 2026 [1] - TPN171 was approved in Uzbekistan in September 2022 and is expected to be approved in China by July 2025, with a market value of RMB 93 billion projected for 2024 [2] Market Context - The biopharmaceutical sector in Suzhou is experiencing growth, with 14 companies in the pipeline for listing on the Hong Kong Stock Exchange, and 5 already having completed regulatory filings [2] - Suzhou has a total of 71 listed companies, with 280 companies overall, including 226 on the domestic A-share market, ranking fifth nationwide [2]

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical sector, specifically recommending the innovative drug and medical device industry chain [5][10]. Core Insights - The pharmaceutical sector shows a positive recovery trend in Q3 2025, with overall revenue growth of 0.6% year-on-year and a net profit increase of 0.3% year-on-year. This indicates a return to growth after previous declines [6][13]. - Specific segments such as medical devices and medical research outsourcing are experiencing significant growth, with revenue and net profit growth rates of 10.6% and 0.6% for medical devices, and 10.9% and 47.9% for medical research outsourcing, respectively [13][14]. - The report highlights a continued recommendation for specific A-share and H-share stocks, including 恒瑞医药 (Hengrui Medicine), 科伦药业 (Kelun Pharmaceutical), and others, indicating strong potential for investment [7][10]. Summary by Sections 1. Continued Recommendation for Innovative Drug and Medical Device Industry Chain - The report continues to recommend the innovative drug and medical device industry chain, maintaining "Overweight" ratings for several A-share stocks including 恒瑞医药, 科伦药业, and others, and H-share stocks like 翰森制药 and 三生制药 [7][10]. 2. Recovery Trend in Pharmaceutical Sector Q3 2025 - The pharmaceutical sector's overall revenue increased by 0.6% year-on-year in Q3 2025, with net profit rising by 0.3%. Medical devices and medical research outsourcing are leading this recovery with notable growth rates [13][14]. 3. Performance of Pharmaceutical Sector in October 2025 - In October 2025, the pharmaceutical sector underperformed compared to the broader market, with the SW pharmaceutical index declining by 1.8% while the Shanghai Composite Index rose by 1.9% [15][26]. 4. Performance of Hong Kong and US Pharmaceutical Sectors - The Hong Kong pharmaceutical sector also underperformed, with the Hang Seng Healthcare index down by 11.1%, while the US pharmaceutical sector showed strength with a 3.5% increase in the S&P healthcare index [26][27]. 5. Valuation and Premium Levels - As of October 31, 2025, the pharmaceutical sector's premium level relative to all A-shares is at a normal level, with a current relative premium rate of 76.7% [25][28].

Core Insights - Suzhou Wangshan Wangshui Biopharmaceutical Co., Ltd. has officially listed on the Hong Kong Stock Exchange, marking the fifth company from Suzhou Industrial Park to go public this year [1][2] - The company aims to innovate in the fields of neuropsychiatry, reproductive health, and viral infections, with a comprehensive integrated system covering the entire drug development process [1] - Wangshan Wangshui's two core products, LV232 and TPN171, are in different stages of development, with LV232 targeting major depressive disorder and TPN171 approved for erectile dysfunction [1][2] Company Overview - Founded in 2013, Wangshan Wangshui is a comprehensive integrated innovative small molecule drug company headquartered in Suzhou Industrial Park [1] - The company has developed a competitive pipeline with two products in commercialization, four in clinical research, and three in preclinical research [1] Product Details - LV232 is a treatment for psychiatric disorders, with a Phase II clinical trial for major depressive disorder set to begin in April 2025 in China, expected to complete by the second half of 2026 [1] - TPN171, a PDE5 inhibitor, was approved in Uzbekistan in September 2022 and is expected to be approved in China by July 2025, targeting erectile dysfunction with a projected market value of RMB 93 billion in 2024, growing to RMB 150 billion by 2035 [2] Market Context - Suzhou has seen a total of 71 companies listed both domestically and internationally, with 14 more companies in the pipeline for potential listing on the Hong Kong Stock Exchange [2] - The city has a total of 280 listed companies, ranking fifth in the country, with 15 new listings this year, including eight domestic listings [2]

Investment Rating - The report maintains a focus on innovative pharmaceuticals and medical devices, highlighting key A-share and H-share targets for investment [6][32]. Core Insights - The pharmaceutical sector showed a good recovery in Q3 2025, with overall revenue increasing by 0.6% year-on-year and net profit attributable to shareholders rising by 0.3% year-on-year [11][32]. - Medical equipment benefited from procurement recovery, with Q3 revenue and net profit growth of 10.6% and 0.6% year-on-year, respectively [11][32]. - Medical R&D outsourcing continued to achieve high growth, with Q3 revenue and net profit growth of 10.9% and 47.9% year-on-year [11][32]. - The offline pharmacy sector improved, with Q3 revenue and net profit growth of 2.1% and 37.8% year-on-year [11][32]. Summary by Sections 1. Focus on Innovative Pharmaceuticals and Medical Devices - Key A-share targets include Jiangsu Heng Rui Medicine, Sichuan Kelun Pharmaceutical, Huadong Medicine, Changchun High-tech Industry, Jiangsu Nhwa Pharmaceutical, WuXi AppTec, Hangzhou Tigermed Consulting, Lepu Medical, APT Medical, and related target Guangdong Zhongsheng Pharmaceutical [6][32]. - Key H-share targets include Hansoh Pharmaceutical Group, 3SBio, Akeso, and related target Innovent Biologics, WuXi AppTec [6][32]. 2. Q3 2025 Pharmaceutical Sector Recovery - The pharmaceutical sector's overall revenue increased by 0.6% year-on-year, with net profit attributable to shareholders up by 0.3% year-on-year [11][32]. - Specific segments such as medical devices and medical R&D outsourcing showed significant growth [11][32]. 3. October 2025 Market Performance - In October 2025, the pharmaceutical sector underperformed the market, with the SW Pharmaceutical and Biological index falling by 1.8% while the SHCOMP rose by 1.9% [14][32]. - The relative premium of the pharmaceutical sector compared to all A-shares was at a normal level, with a current relative premium rate of 76.7% [23][32]. 4. Hong Kong and U.S. Market Performance - The Hong Kong pharmaceutical sector underperformed, with the Hang Seng Healthcare index falling by 11.1% [24][32]. - In contrast, the U.S. S&P 500 healthcare sector rose by 3.5% [24][32].

Group 1: Fund Purchase Restrictions - Recent increase in fund purchase restrictions, particularly for quantitative small-cap funds and QDII funds due to strong performance and overseas investments [1] - Fund companies are proactively limiting purchases to manage inflow and emphasize long-term performance stability [1] Group 2: A-share Tourism Market - A-share tourism sector shows active performance following the announcement of the longest Spring Festival holiday in history, lasting 9 days in 2026 [2] - Increased ticket search volume and travel interest noted, with expectations for a more balanced daily passenger flow during the holiday [2] Group 3: Non-Performing Asset Transfers - Multiple banks are actively announcing non-performing asset transfers, with nearly 90 banks reporting such actions since October, involving over 10 billion yuan [2] - Personal housing loans, consumer loans, and operational loans are the primary categories being transferred [2] Group 4: Hong Kong IPO Market - Hong Kong IPO market has reached 216.47 billion HKD in 2025, marking a significant recovery since 2021 [2] - Continued strong interest in IPOs is expected, with many companies waiting to list [2] Group 5: Financial Distress and Self-Rescue Measures - 178 companies in the A-share market are facing potential delisting risks due to financial indicators, with Q4 performance critical for survival [2] - Companies are taking self-rescue actions, including mergers, asset sales, and restructuring [2] Group 6: Electric Vehicle Industry Transformation - The number of new energy vehicles in China reached 36.89 million by mid-2025, indicating a shift towards smart and connected vehicles [3] - Consumer preferences are evolving, with increased focus on smart driving assistance and interactive experiences [3] Group 7: Low-altitude Logistics Development - Low-altitude logistics is gaining traction, with several provinces launching new policies and routes to enhance industry growth [4] - This emerging logistics method is seen as a cost-effective solution for improving logistics efficiency [4] Group 8: Controlled Nuclear Fusion Investment - Significant capital is flowing into the controlled nuclear fusion sector, with related indices showing over 65% growth this year [4] - The industry is expected to enter a capital expenditure acceleration phase during the 14th Five-Year Plan [4] Group 9: Puma's Restructuring Efforts - Puma reported a 10.4% decline in sales to 1.9557 billion euros in Q3 2025, leading to a net loss of 62.3 million euros [6] - The company plans to cut approximately 900 jobs globally by the end of 2026 as part of cost-reduction measures [6] Group 10: Apple’s Market Strategy - Apple plans to launch a low-cost MacBook and a foldable iPhone in 2026 to address declining sales in the Greater China region [7] - The company is also tightening control over its offline distribution channels to stabilize pricing and order [7] Group 11: Country Garden's Debt Restructuring - Country Garden's offshore debt restructuring plan has received approval from a majority of creditors, with a court hearing scheduled for December 4, 2025 [7] Group 12: Stock Market Movements - U.S. stock indices collectively rose, with the Nasdaq up 0.65% and the Dow Jones up 0.48%, driven by positive economic data and tech stock performance [13] - Bitcoin and Ethereum rebounded significantly after recent declines, indicating a recovery in the cryptocurrency market [13]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 映恩生物 (「本公司」) 呈交日期: 2025年11月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 09606 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 200,000,000 | USD | | 0.0001 | USD | | 20,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 200,000,000 | USD | | 0.0001 | USD | | 20,000 | 本月底法定/註冊股本總額： ...